Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?
- Published In:
- Frontiers in aging neuroscience, 6, 186 (2014)
- Authors:
- Qiu, Wei Qiao, Zhu, Haihao
- Database ID:
- RPEP-02480
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02480APA
Qiu, Wei Qiao; Zhu, Haihao. (2014). Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?. Frontiers in aging neuroscience, 6, 186. https://doi.org/10.3389/fnagi.2014.00186
MLA
Qiu, Wei Qiao, et al. "Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?." Frontiers in aging neuroscience, 2014. https://doi.org/10.3389/fnagi.2014.00186
RethinkPeptides
RethinkPeptides Research Database. "Amylin and its analogs: a friend or foe for the treatment of..." RPEP-02480. Retrieved from https://rethinkpeptides.com/research/qiu-2014-amylin-and-its-analogs
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.